Monoamine Oxidase Inhibitors (MAOIs)

Monoamine oxidase inhibitors (MAOIs) are a class of medications that block the activity of monoamine oxidase enzymes, which are responsible for degrading neurotransmitters such as serotonin, norepinephrine, and dopamine By inhibiting this breakdown, MAOIs increase the synaptic concentrations and signaling of these monoamines within the central nervous system Historically established as the first generation of antidepressants, they are primarily utilized for treatment-resistant major depressive d...

Monoamine oxidase inhibitors (MAOIs) are a class of medications that block the activity of monoamine oxidase enzymes, which are responsible for degrading neurotransmitters such as serotonin, norepinephrine, and dopamine

By inhibiting this breakdown, MAOIs increase the synaptic concentrations and signaling of these monoamines within the central nervous system Due to significant risks of hypertensive crisis from dietary tyramine and severe drug interactions, their clinical use is generally reserved for cases refractory to other therapies

Historically established as the first generation of antidepressants, they are primarily utilized for treatment-resistant major depressive disorder, atypical depression, and anxiety disorders, as well as in the management of Parkinson disease via selective MAO-B inhibition Due to significant risks of hypertensive crisis from dietary tyramine and severe drug interactions, their clinical use is generally reserved for cases refractory to other therapies

Historically established as the first generation of antidepressants, they are primarily utilized for treatment-resistant major depressive disorder, atypical depression, and anxiety disorders, as well as in the management of Parkinson disease via selective MAO-B inhibition